To the Editor: In their Perspective article, De Cock and El-Sadr (March 7 issue)1 highlight the need for data on when to start antiretroviral therapy (ART) for HIV-infected people in Africa who have CD4+ counts above 350 cells per cubic millimeter. However, their proposed solution — a new randomized, controlled trial in Africa — is flawed
BACKGROUND: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuber...
Recently published WHO guidance recommends starting ART in HIV-infected adults with CD4 counts of ≤3...
Translating evidence from clinical trials to routine care can take many years, particularly in low-i...
In this article, the scientific evidence and professional guidelines regarding the timing of antiret...
CC999999/Intramural CDC HHS/United States2019-05-29T00:00:00Z25541162PMC6540745636
reproduction in any medium, provided the original work is properly cited. In this issue of the Journ...
The history of the HIV–AIDS epidemic was profoundly altered by the introduction of antiretroviral th...
Antiretroviral therapy (ART) has transformed the lives of individuals with HIV in many parts of sub-...
Combination antiretroviral therapy (ART) has greatly improved the prognosis of HIV-infected individu...
BACKGROUND: Recent evidence from developed and developing countries shows clear clinical and public ...
Introduction: As global policy evolves toward initiating lifelong antiretroviral therapy (ART) regar...
Early use of highly active antiretroviral treatment (ART) in people living with HIV for HIV preventi...
Data from CD4-guided structured treatment interruptions strategies trials performed in industrialise...
Copyright © 2013 Gerardo Alvarez-Uria et al. This is an open access article distributed under the Cr...
Background Antiretroviral therapy (ART) prevents human immunodeficiency virus (HIV) disease pro-gres...
BACKGROUND: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuber...
Recently published WHO guidance recommends starting ART in HIV-infected adults with CD4 counts of ≤3...
Translating evidence from clinical trials to routine care can take many years, particularly in low-i...
In this article, the scientific evidence and professional guidelines regarding the timing of antiret...
CC999999/Intramural CDC HHS/United States2019-05-29T00:00:00Z25541162PMC6540745636
reproduction in any medium, provided the original work is properly cited. In this issue of the Journ...
The history of the HIV–AIDS epidemic was profoundly altered by the introduction of antiretroviral th...
Antiretroviral therapy (ART) has transformed the lives of individuals with HIV in many parts of sub-...
Combination antiretroviral therapy (ART) has greatly improved the prognosis of HIV-infected individu...
BACKGROUND: Recent evidence from developed and developing countries shows clear clinical and public ...
Introduction: As global policy evolves toward initiating lifelong antiretroviral therapy (ART) regar...
Early use of highly active antiretroviral treatment (ART) in people living with HIV for HIV preventi...
Data from CD4-guided structured treatment interruptions strategies trials performed in industrialise...
Copyright © 2013 Gerardo Alvarez-Uria et al. This is an open access article distributed under the Cr...
Background Antiretroviral therapy (ART) prevents human immunodeficiency virus (HIV) disease pro-gres...
BACKGROUND: In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)-associated tuber...
Recently published WHO guidance recommends starting ART in HIV-infected adults with CD4 counts of ≤3...
Translating evidence from clinical trials to routine care can take many years, particularly in low-i...